Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OPRX
stocks logo

OPRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
30.91M
-4.34%
0.224
-25.24%
23.03M
+5.01%
0.043
-45.84%
28.14M
-3.6%
0.155
-35.42%
Estimates Revision
The market is revising Upward the revenue expectations for OptimizeRx Corporation (OPRX) for FY2025, with the revenue forecasts being adjusted by 1.57% over the past three months. During the same period, the stock price has changed by -22.16%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.57%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+15.13%
In Past 3 Month
Stock Price
Go Down
down Image
-22.16%
In Past 3 Month
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.97 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.97 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.650
sliders
Low
17.00
Averages
24.97
High
32.00
Current: 14.650
sliders
Low
17.00
Averages
24.97
High
32.00
Stephens
Jeff Garro
Equal Weight
downgrade
$20 -> $17
2025-11-17
Reason
Stephens
Jeff Garro
Price Target
$20 -> $17
2025-11-17
downgrade
Equal Weight
Reason
Stephens analyst Jeff Garro lowered the firm's price target on OptimizeRx to $17 from $20 and keeps an Equal Weight rating on the shares. Noting that shares are up greater than 200% year-to-date, the firm views the current risk/reward as balanced and looks to confirm business momentum exceeding conservative pipeline assumptions.
B. Riley
Buy
upgrade
$18 -> $28
2025-11-07
Reason
B. Riley
Price Target
$18 -> $28
2025-11-07
upgrade
Buy
Reason
B. Riley raised the firm's price target on OptimizeRx to $28 from $18 and keeps a Buy rating on the shares. The firm views the company's Q3 report as strong.
Lake Street
Buy
maintain
$20 -> $24
2025-11-07
Reason
Lake Street
Price Target
$20 -> $24
2025-11-07
maintain
Buy
Reason
Lake Street raised the firm's price target on OptimizeRx to $24 from $20 and keeps a Buy rating on the shares, telling investors that the firm was "pleased" with the company's third consecutive strong quarter and guide. The FY26 revenue midpoint equates to growth of 13%, which compares favorably to the 11% consensus, the analyst noted.
Roth Capital
Buy
upgrade
$27 -> $32
2025-11-07
Reason
Roth Capital
Price Target
$27 -> $32
2025-11-07
upgrade
Buy
Reason
Roth Capital raised the firm's price target on OptimizeRx to $32 from $27 and keeps a Buy rating on the shares. The company reported strong Q3 results and beat its guidance again, while its visibility is clearly much improved after 2024's weak execution, the analyst tells investors in a research note.
Stifel
David Grossman
Buy
maintain
$18 -> $21
2025-11-07
Reason
Stifel
David Grossman
Price Target
$18 -> $21
2025-11-07
maintain
Buy
Reason
Stifel analyst David Grossman raised the firm's price target on OptimizeRx to $21 from $18 and keeps a Buy rating on the shares. Revenue for the quarter materially outperformed, which drove significant EPS outperformance, the analyst tells investors in a research note. The firm added that it believes there's a foundation for ongoing double-digit growth and expanding margins.
Citizens JMP
Constantine Davides
Outperform
maintain
$23 -> $24
2025-11-07
Reason
Citizens JMP
Constantine Davides
Price Target
$23 -> $24
2025-11-07
maintain
Outperform
Reason
Citizens JMP analyst Constantine Davides raised the firm's price target on OptimizeRx to $24 from $23 and keeps an Outperform rating on the shares. OptimizeRx showed continuing momentum in Q3 and established formal guidance for 2026, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for OptimizeRx Corp (OPRX.O) is 20.75, compared to its 5-year average forward P/E of 60.73. For a more detailed relative valuation and DCF analysis to assess OptimizeRx Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
60.73
Current PE
20.75
Overvalued PE
98.41
Undervalued PE
23.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
55.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
102.58
Undervalued EV/EBITDA
7.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.03
Current PS
0.00
Overvalued PS
11.53
Undervalued PS
0.53
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

OPRX News & Events

Events Timeline

(ET)
2025-11-06
16:22:16
OptimizeRx projects FY26 revenue between $118M and $124M, with consensus at $119.19M.
select
2025-11-06
16:21:38
OptimizeRx increases FY25 revenue forecast to $105M-$109M, up from $104M-$108M.
select
2025-11-06
16:20:21
OptimizeRx announces Q3 earnings per share of 20 cents, surpassing consensus estimate of 5 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-17Benzinga
Stephens & Co. Keeps Equal-Weight Rating on OptimizeRx, Reduces Price Target to $17

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information that help traders succeed in the stock market.

[object Object]
Preview
4.0
11-17NASDAQ.COM
Top Strong Buy Stocks for November 17: ROKU, AVPT, and Others

  • Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Roku, AvePoint, eToro Group, Northrim BanCorp, and OptimizeRx, all of which have seen significant increases in their earnings estimates over the past 60 days.

  • Quantum Computing Revolution: Quantum computing is emerging as a major technological advancement, with major companies like Microsoft, Google, and Amazon actively integrating it into their operations, indicating its rapid development.

  • Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this technology.

  • Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, encouraging readers to explore these investment options further.

[object Object]
Preview
9.5
11-10NASDAQ.COM
Transcript of OptimizeRx (OPRX) Earnings Call for Q3 2025
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OptimizeRx Corp (OPRX) stock price today?

The current price of OPRX is 14.65 USD — it has increased 2.3 % in the last trading day.

arrow icon

What is OptimizeRx Corp (OPRX)'s business?

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

arrow icon

What is the price predicton of OPRX Stock?

Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.97 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OptimizeRx Corp (OPRX)'s revenue for the last quarter?

OptimizeRx Corp revenue for the last quarter amounts to 26.07M USD, increased 22.33 % YoY.

arrow icon

What is OptimizeRx Corp (OPRX)'s earnings per share (EPS) for the last quarter?

OptimizeRx Corp. EPS for the last quarter amounts to 0.04 USD, decreased -108.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for OptimizeRx Corp (OPRX)'s fundamentals?

The market is revising Upward the revenue expectations for OptimizeRx Corporation (OPRX) for FY2025, with the revenue forecasts being adjusted by 1.57% over the past three months. During the same period, the stock price has changed by -22.16%.
arrow icon

How many employees does OptimizeRx Corp (OPRX). have?

OptimizeRx Corp (OPRX) has 106 emplpoyees as of December 05 2025.

arrow icon

What is OptimizeRx Corp (OPRX) market cap?

Today OPRX has the market capitalization of 272.90M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free